GLPwatch
[Onset of type 1 diabetes after treatment with online-prescribed semaglutide].
Ugeskr Laeger · 2026
Last updated 2026-07-22| Journal | Ugeskr Laeger, 2026 |
|---|---|
| Citations | 0 |
| Molecules | semaglutide |
Abstract
A 49-year-old woman developed new-onset type 1 diabetes after initiating Wegovy (semaglutide) via an online clinic, without prior screening. She experienced rapid weight loss and hyperglycemia symptoms. Blood tests indicated high GAD65 and low C-peptide. The case underscores the need for biochemical screening and follow-up in digital obesity care.
Verbatim abstract via PubMed 41738100 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.